Latest Content

Maximillian Fink, MD, a pioneering psychiatrist and advocate for ECT, leaves a lasting legacy in neuropsychiatry and education.

Discover how best to approach ADHD assessments and utilize tools such as the Mentavi Diagnostic Evaluation, which can help improve patient care and reduce stigma.

Uzedy, a once-monthly extended release long-acting injectable, is now FDA approved for bipolar I disorder.

New research reveals that benzodiazepines and antipsychotics increase mortality risk in hospice patients with Alzheimer disease and dementia.

A reproductive psychiatrist discusses the implications of recent FDA announcements on medication use during pregnancy, emphasizing the importance of mental health for mothers and babies.

Explore the complexities of aripiprazole in bipolar disorder treatment, including its efficacy and proper prescribing practices.

Discover the most effective components of cognitive behavioral therapy for chronic insomnia, enhancing treatment outcomes and patient care strategies.

Cingulate's CTx-1301, a novel ADHD treatment, gains FDA review, promising rapid relief and sustained efficacy for patients.

AI chatbots prioritize user engagement over mental health, risking harm to vulnerable users. Explore the urgent need for ethical programming and safety measures.

Data presented at the ECNP Conference showed CT-155 has promise in reducing negative symptoms of schizophrenia.

New data indicates safety of seltorexant and its pharmacokinetics in treating adolescent depression, supporting its potential as an effective adjunct therapy.

New research reveals women with ADHD are diagnosed 5 years later than men, highlighting the need for improved awareness and early intervention.

Discover how Mentavi Health's innovative ADHD assessment enhances diagnosis speed, accuracy, and patient engagement in mental health care.